IBRX - Immunitybio - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

IBRX is currently covered by 2 analysts with an average price target of $10.11. This is a potential upside of $7.7 (319.5%) from yesterday's end of day stock price of $2.41.

Immunitybio's activity chart (see below) currently has 22 price targets and 33 ratings on display. The stock rating distribution of IBRX is 22.22% HOLD and 77.78% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 56.36% with an average time for these price targets to be met of 202.75 days.

Highest price target for IBRX is $30, Lowest price target is $5, average price target is $17.5.

Most recent stock forecast was given by JASON KOLBERT from D. BORAL CAPITAL on 25-Jul-2025. First documented stock forecast 16-May-2017.

Best performing analysts who are covering IBRX - Immunitybio:

Kelly Shi Joseph Catanzaro Joel Beatty Jason Kolbert

Currently out of the existing stock ratings of IBRX, 4 are a HOLD (22.22%), 14 are a BUY (77.78%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$30

$27.54 (1119.51%)

$30

11 days ago
(25-Jul-2025)

0/14 (0%)

$27.14 (948.95%)

Hold

$5

$2.54 (103.25%)

$4.75

2 months 16 days ago
(20-May-2025)

5/11 (45.45%)

$2.1 (72.41%)

103

Buy

$5

$2.54 (103.25%)

$8

2 years 2 months 21 days ago
(15-May-2023)

2/2 (100%)

$1.78 (55.28%)

431

Sell

$0.8

$-1.66 (-67.48%)

$1.25

6 years 2 months 5 days ago
(31-May-2019)

4/5 (80%)

$-0.23 (-22.33%)

277

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is IBRX (Immunitybio) average time for price targets to be met?

On average it took 202.75 days on average for the stock forecasts to be realized with a an average price target met ratio 56.36

Which analyst has the current highest performing score on IBRX (Immunitybio) with a proven track record?

KELLY SHI

Which analyst has the current lower performing score on IBRX (Immunitybio) with a proven track record?

JASON KOLBERT

Which analyst has the most public recommendations on IBRX (Immunitybio)?

Kelly Shi works at JEFFERIES and has 4 price targets and 2 ratings on IBRX

Which analyst is the currently most bullish on IBRX (Immunitybio)?

Jason Kolbert with highest potential upside - $27.54

Which analyst is the currently most reserved on IBRX (Immunitybio)?

Joel Beatty with lowest potential downside - -$1.66

Immunitybio in the News

Immunitybio (IBRX) Targets $80 Million Capital Raise for Business Operations

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the penny stocks that will skyrocket. On July 25, the company confirmed it is eyeing $80 million in gross proceeds on the execution of a securities purchase agreement as part of a registered direct offering. It also plans to issue common stock and warrants for the purchase of additional...

ImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder Cancer

We recently compiled a list of 11 Best Future Stocks to Buy Now. ImmunityBio, Inc. stands eleventh on our list. ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best future stocks to buy now. It is transforming cancer care through immunotherapies that activate the body’s natural defenses. Its lead therapy, ANKTIVA (nogapendekin alfa inbakicept), has already...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?